XSHE
000525
Market cap889mUSD
Oct 09, Last price
4.61CNY
1D
0.88%
1Q
13.55%
Jan 2017
-73.23%
Name
Nanjing Red Sun Co Ltd
Chart & performance
P/E
—
P/S
1.95
EPS
—
Div yield, %
—
Shrs. gr., 5y
17.60%
Rev. gr., 5y
-5.20%
Revenues
3.08b
+2.42%
Net income
-379m
L
CFO
177m
-48.96%
Dividend
Jul 19, 20190.15 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1989 and headquartered in Nanjing, China, Nanjing Red Sun Co.,Ltd. is an enterprise focused on the research, manufacturing, and distribution of various chemicals, with a primary emphasis on pesticides, within the Chinese market. Its comprehensive product portfolio encompasses herbicides, insecticides, fungicides, animal nutrition supplements, three-drug intermediates, and specialty fine chemicals. Additionally, the company provides expert technical advisory and customized product development services to its clients.
Key people
Yuan Cheng
Vice Chairman of the Board · since 2024
Yong Zhao
Chief Financial Officer
Qiongzao Bao
Deputy General Manager, Director · since 2025
Zhizhong Chen
Deputy General Manager
Liming Hu
Deputy General Manager · since 2024
Hongming Wang
Deputy General Manager · since 2012
Guoping Wang
Deputy General Manager
Rong Wu
Deputy General Manager · since 2025
Zhonglu Wu
Deputy General Manager
Libing Zhang
Deputy General Manager, Director · since 2024
Lanping Zhang
Deputy General Manager · since 2024
Jizhen Chen
Secretary of the Board · since 2024
Zongze Jiang
Secretary of the Board · since 2026
Rongmao Hu
Director · since 2025
Yi Yang
Chairman of the Board · since 2025
Bin Yang
Deputy General Manager, Director · since 2024
Peilin Mu
Independent Director · since 2024
Zhongxiong Wei
Independent Director · since 2024
Zhen Yan
Independent Director
Headquarters & legal address
南京市江宁区竹山南路589号
南京市, JS 210000
CN
南京市, JS 210000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||